"With clinical outcomes rightly considered non-negotiable, this data shows that community oncology is seeking new frameworks for understanding the comprehensive value of novel therapies and other high-cost treatments," said Dr. Jeffrey Scott, chief medical officer of Integra Connect. "It is not an effort they believe that they can – or want to – undertake alone. While oncologists say pharma is not at the table today, they're expressing the need for new data and insights that only manufacturers can provide. In addition, they foresee the need for closer payer cooperation in order for future generations of value-based reimbursement models to be successful."


About Integra Connect

Integra Connect delivers a comprehensive, integrated suite of cloud-based technologies and services that enable specialty groups to optimize clinical and financial performance as reimbursement shifts to value-based models. Connected by the IntegraCloud platform, the company's core applications span population health including care management; advanced analytics; registry and regulatory reporting; specialty-specific EHR; practice management; and revenue cycle management. All are designed to help specialty practices transform operationally in adherence with complex regulations, including MACRA program requirements. Integra Connect partners with large groups in the U.S. focused on oncology and urology, as well as with other key healthcare constituents, including emergency medical services firms, hospitalist groups and life sciences companies.


SOURCE Integra Connect

Back to HCB News

Rad Oncology Homepage